The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksClontarf Regulatory News (CLON)

Share Price Information for Clontarf (CLON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0375
Bid: 0.035
Ask: 0.04
Change: 0.00 (0.00%)
Spread: 0.005 (14.286%)
Open: 0.0375
High: 0.0375
Low: 0.0375
Prev. Close: 0.0375
CLON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Joint Venture Agreement and TVR

5 May 2023 07:00

RNS Number : 4828Y
Clontarf Energy PLC
05 May 2023
 

 

5th May 2023

 

Clontarf Energy plc

("Clontarf" or "the Company")

 

Update on Joint Venture Agreement and TVR

 

Clontarf Energy plc (AIM: CLON) is pleased to announce that, further to its announcement on 28 March 2023, all conditions precedent have now been satisfied with respect to the JV with NEXT-ChemX coming into force. In this regard, Clontarf has paid NEXT-ChemX Corporation US$500,000 and will now proceed with the issue to NEXT-ChemX of 385 million new Ordinary Shares in the capital of Clontarf ("Consideration Shares"), of which half will be subject to a 12-month lock in requirement. NEXT-ChemX has also provided Clontarf with US$500,000 proof of funds.

 

 

Chairman, David Horgan, commented:

 

"Completion of Clontarf's joint venture with our preferred Direct Lithium Extraction partner is another important milestone.

 

"Part of the transaction is the current and future swapping of shares between Clontarf Energy plc and NEXT-ChemX companies.

 

"We are also considering ways to extend Clontarf's upside potential beyond our promising Bolivian joint venture.

 

"Lithium demand continues to grow, as are purity requirements in the Lithium-ion battery industry. Recent discussions in Asia reinforced our belief in market demand, particularly for environmentally-friendly and cost-efficient Lithium from brines.

 

"Our team has been working with various licence-holders and regulatory bodies to provide sufficient volumes of priority brines for laboratory test-work. Once these tests have yielded adequate results, we expect to move to pilot plant volumes. This work should enable confirmation of the commerciality of the NEXT-ChemX DLE process and move to the application of the technology across a number of lithium brine projects."

 

 

 

 

Further details on the Consideration Shares and TVR

 

The Consideration Shares will rank pari passu with the Company's existing Ordinary Shares. Application has been made for the Consideration Shares to be admitted to trading on AIM ("Admission") and it is expected that such Admission will become effective on or around 10th May 2023. The issue of the Consideration Shares is being satisfied by the Directors' existing authority to allot shares free of pre-emption rights.

 

Following the Admission of the Consideration Shares, there will be a total of 4,755,826,117 Ordinary Shares in issue with each share carrying the right of one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information please visit http://clontarfenergy.com or contact:

 

Clontarf Energy

David Horgan, Chairman

Jim Finn, Director

+353 (0) 1 833 2833

Nominated & Financial Adviser

Strand Hanson Limited

Rory Murphy

Ritchie Balmer

+44 (0) 20 7409 3494

Broker

Novum Securities Limited

Colin Rowbury

+44 (0) 207 399 9400

Public Relations

BlytheRay

Megan Ray

+44 (0) 207 138 3206

 

Teneo

Luke Hogg

Alan Tyrrell

 

+353 (0) 1 661 4055

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDAIMATMTIMBIJ
Date   Source Headline
10th Apr 20241:35 pmRNSGrant of Share Options
18th Mar 20247:00 amRNSBolivia Update, Fundraising and TVR
6th Mar 202410:33 amRNSEncouraging Bolivian Brines Progress
5th Feb 20247:00 amRNSSouth American Brines Progress
25th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
1st Aug 202310:38 amRNSGrant of Share Options
13th Jul 202312:35 pmRNSResult of AGM and Corporate Update
22nd Jun 202312:32 pmRNSPosting of Annual Report and Notice of AGM
8th Jun 20237:00 amRNSPreliminary Results
1st Jun 20237:00 amRNS£350,000 Fundraising and Corporate Update
5th May 20237:00 amRNSUpdate on Joint Venture Agreement and TVR
28th Mar 202310:24 amRNSJV Agreement on Direct Lithium Extraction Bolivia
17th Feb 202311:05 amRNSSecond Price Monitoring Extn
17th Feb 202311:00 amRNSPrice Monitoring Extension
15th Feb 20237:00 amRNSJV HoA on Direct Lithium Ion Extraction in Bolivia
17th Jan 202310:34 amRNSGrant of Share Options
16th Jan 20237:00 amRNS£1.3 million Fundraising and Corporate Update
8th Nov 20224:40 pmRNSSecond Price Monitoring Extn
8th Nov 20224:35 pmRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSInterim Results for the period ended 30 June 2022
5th Sep 20227:02 amRNSShare Price Movement and Shareholder Update
4th Aug 20221:00 pmRNSResult of AGM and Capital Reorganisation
1st Jul 202211:04 amRNSDirector Change
29th Jun 202210:30 amRNSPosting of Annual Report
22nd Jun 20227:00 amRNSPreliminary Results for the Year Ended 31 Dec 2021
14th Jun 20227:00 amRNSSasanof-1 well completion
6th Jun 20227:00 amRNSSasanof-1 well final result
6th Jun 20227:00 amRNSResult of General Meeting
30th May 20228:00 amRNSSasanof-1 well drilling update
27th May 20227:00 amRNSSasanof-1 well spudding
23rd May 20227:00 amRNSSasanof-1 well mobilisation update
20th May 20224:41 pmRNSSecond Price Monitoring Extn
20th May 20224:36 pmRNSPrice Monitoring Extension
18th May 20222:06 pmRNSSecond Price Monitoring Extn
18th May 20222:00 pmRNSPrice Monitoring Extension
18th May 20227:00 amRNSSasanof-1 well mobilisation update
17th May 202211:00 amRNSPrice Monitoring Extension
12th May 202211:53 amRNSUpdate on Sasanof-1 well
11th May 20223:58 pmRNSNotice of General Meeting
10th May 20227:00 amRNSConsideration Shares to be Admitted to Trading
9th May 20227:00 amRNSAcquisition of 10% of Sasanof Prospect
27th Apr 20221:02 pmRNSPlacing to raise £3,500,000
12th Jan 20224:40 pmRNSIssue of Warrants and RPT
20th Sep 20214:41 pmRNSSecond Price Monitoring Extn
20th Sep 20214:36 pmRNSPrice Monitoring Extension
15th Sep 20217:00 amRNSInterim Statement
23rd Jun 202111:35 amRNSResult of Annual General Meeting and Board Changes
7th Jun 202110:50 amRNSPosting of Annual Report and Notice of AGM
24th May 20214:11 pmRNSTR-1: Notification of major holdings
20th May 20213:58 pmRNSTR-1: Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.